Who is sponsoring NCT05605756?

NCT05605756 is sponsored by Beth Israel Deaconess Medical Center.

What drugs are being tested in NCT05605756?

Interventions in NCT05605756: OnabotulinumtoxinA 145 UNT [Botox].

What condition does NCT05605756 study?

NCT05605756 studies Drug-resistant Focal Seizure.

Is NCT05605756 still recruiting?

NCT05605756 is currently terminated. Last updated 23 January 2025.

Last reviewed 2025-01-23 · How we verify

NCT05605756

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BOTOX Effects on Seizure Severity and Susceptibility

Terminated Phase 4 Last updated 23 January 2025

What this trial tests

Phase 4 trial testing OnabotulinumtoxinA 145 UNT [Botox] in Drug-resistant Focal Seizure in 3 participants. Terminated before completion.

Timeline

1 March 2023

Primary endpoint
1 December 2024

1 December 2024

Quick facts

Lead sponsor	Beth Israel Deaconess Medical Center
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	1 March 2023
Primary completion	1 December 2024
Estimated completion	1 December 2024
Sites	1 location across United States

Drugs / interventions tested

OnabotulinumtoxinA 145 UNT [Botox] — full drug profile →

Conditions studied

Drug-resistant Focal Seizure — all drugs for Drug-resistant Focal Seizure →

Sponsor

Beth Israel Deaconess Medical Center

Who can join

Adults 18 to 85, any sex, with Drug-resistant Focal Seizure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research is to determine whether BOTOX injections will reduce seizure frequency and severity. We chose to test its effects on epilepsy because epilepsy and migraine have common features so, are often treated with common drugs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Beth Israel Deaconess Medical Center trials

Trials by the same sponsor.

NCT07352657 — Remote Alert Pathway To Optimize CaRe of Cardiac Implantable Electrical Devices: The RAPTOR-CIED Study (Main Phase) · NA · not yet recruiting
NCT07531602 — Effect of PEEP on Cardiac Function · NA · not yet recruiting
NCT07534683 — Primed to Thrive: Investigating the Combined Impact of Mindfulness Education and Meditation Practice on Psychological an · NA · not yet recruiting
NCT07277244 — Low-Intensity Mechanical Ventilation in the Operating Room: a Pilot Study · NA · enrolling by invitation
NCT06896474 — SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05605756 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beth Israel Deaconess Medical Center
Last refreshed: 23 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05605756.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing